Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acarovac Quattro
- Development stage
- Unknown
- Lead developer
- Allergy Therapeutics
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Acarovac Quattro is an ultra-short course subcutaneous immunotherapy vaccine developed for the treatment of house dust mite (HDM) allergy, specifically perennial allergic rhinitis and allergic asthma. It is based on allergoids derived from Dermatophagoides pteronyssinus and Dermatophagoides farinae (house dust mites), adsorbed onto a biodegradable depot adjuvant system composed of microcrystalline tyrosine (MCT) and monophosphoryl lipid A (MPL). This formulation builds upon Allergy Therapeutics' existing platforms, such as Pollinex Quattro and Acarovac Plus, aiming to improve patient convenience by reducing the number of injections required compared to traditional immunotherapies. The mechanism of action involves immunomodulation—specifically, inducing immune tolerance to HDM allergens through repeated controlled exposure, which leads to increased allergen-specific IgG4 antibodies and anti-inflammatory cytokines like IL-10 while reducing Th2-mediated responses such as IL-4 production. Clinical studies have shown improvements in symptom scores, quality of life measures, and high patient satisfaction with a favorable safety profile[1][2][5][6][9].
- Brand names
- Acarovac Quattro
- Other names
- Acarovac MPL
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Acarovac Quattro.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acarovac Quattro.